Zafgen Obesity Drug Trial on Hold After Patient Deaths
- Company says patient died of blood blockages in the lungs
- U.S. Food and Drug Administration stops trial from continuing
This article is for subscribers only.
Zafgen Inc. said its trial of an experimental drug to fight obesity was placed on hold by U.S. regulators after a second patient died.
The trial, in patients with a rare genetic disease called Prader-Willi syndrome that causes overeating, was a key study Zafgen needed to finish leading up to a U.S. Food and Drug Administration decision on whether to approve the drug for those patients.